Search Results 71-80 of 17193 for GnRH

1. https://www.mayoclinic.org/arabic_organization_concepts.xml

2. https://www.mayoclinic.org/spanish_organization_concepts.xml

3. Publications - Zech G. Franks, M.D. - Mayo Clinic

   Franks ZG, Nandakumar K, Santhanam L, Lester L, Walsh JM, Dalesio NM. ACE2 and TAS2R38 receptor expression in pediatric and adult patients in the nasal and ...

4. Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer - Mayo Clinic

   Patients on GnRH analog must have therapy initiated at least 4 weeks before Cycle 1, Day 1, and treatment must be continued throughout the study. General ...

5. A Trial to Investigate Long Term Effectiveness and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency - Mayo Clinic

   Inclusion Criteria: - Signing of the trial specific informed consent. - Completion of the treatment period and Visit 7 assessments of trial TCH-306, ...

6. Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   ... (GnRH) analog that was initiated ≥ 4 weeks prior to first dose of study treatment and must be continued throughout the study. Expansion Cohort 7: Subjects ...

7. Study of Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer - Mayo Clinic

   Use of GNRH analogues for ovarian suppression is not considered endocrine therapy for the purposes of this criterion. Note: Adjuvant treatment with ...

9. A Study Of Cancer Therapy In The Patients’ Homes Versus In Clinic In Black Men With Advanced Or Metastatic Prostate Cancer - Mayo Clinic

   ... GnRh antagonists, estrogens, or older antiandrogens are allowed but combinations of oral regimens only are not permitted). Patients who are anticipated to ...

10. A Study to Test the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors - Mayo Clinic

    Subjects receiving Gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participate. The patient has not received any other type of ...